ArticleFrontiers in oncology2022

Cost-effectiveness analysis of sintilimab plus chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.

Maojin You et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.